文献类型：期刊文献

英文题名：The microbiota-tryptophan-brain axis in neurodegenerative diseases: pathogenic mechanisms, disease-specific roles, and translational therapeutics

作者：Wang, Ziyi[1];Li, Lu[1];Dong, Yuhan[1];Zhang, Yamin[2]

第一作者：王震宇;王芝意

通信作者：Zhang, YM[1]

机构：[1]Gansu Univ Chinese Med, Clin Med Coll 1, Gansu Prov Hosp, Lanzhou, Gansu, Peoples R China;[2]Gansu Prov Hosp, Dept Neurol, Lanzhou, Gansu, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Prov Hosp, Dept Neurol, Lanzhou, Gansu, Peoples R China.

年份：2026

卷号：17

外文期刊名：FRONTIERS IN MICROBIOLOGY

收录：;Scopus(收录号：2-s2.0-105040935546);WOS:【SCI-EXPANDED(收录号:WOS:001782182000001)】；

基金：The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the Gansu Provincial Joint Research Fund of Science and Technology Planning Project (grant no. 24JRRA890).

语种：英文

外文关键词：Alzheimer's disease; Aryl hydrocarbon receptor; Microbiota-gut-brain axis; neurodegenerative diseases; Parkinson's disease; tryptophan

摘要：The pathogenesis of neurodegenerative diseases (NDDs) such as Alzheimer's disease (AD) and Parkinson's disease (PD) is very complex. Recent studies have shown that gut microbiota and their metabolites play a key role in the progression of these diseases. Tryptophan (Trp) is an essential amino acid, which mainly produces a variety of biologically active compounds in the intestine through the metabolism of indole pathway, Kynurenine pathway (KP) and serotonin pathway, including indole derivatives, Kynurenine (KYN) and serotonin (5-HT). These metabolites affect the central nervous system (CNS) through the Microbiota-gut-brain axis (MGBA) and affect CNS in a variety of mechanisms, including immune regulation, neuroprotection and maintenance of intestinal barrier function. They are involved in key pathological processes such as neuroinflammation, oxidative stress and pathological protein aggregation. This paper systematically reviews the mechanism of the role of Trp metabolites derived from gut microbiota in NDDs, and explores their specific roles in AD, PD, Amyotrophic Lateral Sclerosis (ALS) and Huntington's disease (HD), and summarizes the potential therapeutic value of the current pathway strategy. These strategies include nutritional intervention, targeted microbiome therapy [such as probiotic and fecal microbiota transplantation (FMT)], and metabolite-derived drugs. Future research must clarify its dynamic mechanism in the human body, develop relevant biomarkers, and promote personalized prevention and treatment strategies through clinical transformation, so as to provide a new direction for early intervention and treatment of NDDs.